Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Medtronic
UBS
Federal Trade Commission
Cipla
Fish and Richardson

Generated: August 19, 2019

DrugPatentWatch Database Preview

Patent: 10,251,778

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,251,778
Title:Therapeutics dispensing device and methods of making same
Abstract: A therapeutics delivery system, and methods of making and using same, are disclosed for environments that rapidly clear any injected therapeutics, such as a patient\'s eye. The therapeutics delivery system releases the drug in a therapeutically effective concentration for a desired duration of time with a predefined drug kinetics. In one embodiment, the embodiments of the present disclosure release a therapeutically effective concentration for a longer time period than other delivery systems, for instance from a day to a week. Certain embodiments comprise a therapeutics dispensing device comprising a biodissolvable hydrogel matrix for long term drug release that allows the device to be placed directly at the injured site, e.g., onto the surface at or near the injury, and retained there rather than through injection, whether locally or systematically.
Inventor(s): Acharya; Ghanashyam (Houston, TX), Pflugfelder; Stephen C. (Houston, TX), De Paiva; Cintia S. (Houston, TX), Simpson; Jennifer L. (Irvine, CA)
Assignee: Baylor College of Medicine (Houston, TX) REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)
Application Number:14/420,295
Patent Claims:see list of patent claims

Details for Patent 10,251,778

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Try a Free Trial Baylor College of Medicine (Houston, TX) REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) 2032-08-06 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Try a Free Trial Baylor College of Medicine (Houston, TX) REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) 2032-08-06 RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Federal Trade Commission
Colorcon
QuintilesIMS
AstraZeneca
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.